CSIMarket



Gilead Sciences Inc   (GILD)
Other Ticker:  
 
 

GILD's Operating Income Growth by Quarter and Year

Gilead Sciences Inc 's Operating Income results by quarter and year




GILD Operating Income (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - 940.00 2,651.00 1,093.00
III Quarter September - 3,842.00 2,001.00 -1,473.00
II Quarter June - 2,246.00 -2,983.00 2,430.00
I Quarter March 197.00 2,890.00 2,402.00 2,237.00
FY   197.00 9,918.00 4,071.00 4,287.00



GILD Operating Income first quarter 2022 Y/Y Growth Comment
Gilead Sciences Inc reported drop in Operating Income in the first quarter 2022 by -93.18% to $ 197.00 millions, from the same quarter in 2021.
The fall in the first quarter 2022 Gilead Sciences Inc 's Operating Income compares unfavorably to the Company's average Operating Income jump of 41.57%.

Looking into first quarter 2022 results within Biotechnology & Pharmaceuticals industry 22 other companies have achieved higher Operating Income growth. While Gilead Sciences Inc ' s Operating Income meltdown of -93.18% ranks overall at the positon no. 1927 in the first quarter 2022.

Explain Operating Income growth


GILD Operating Income ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - -64.54 % 142.54 % -4.46 %
III Quarter September - 92 % - -
II Quarter June - - - 6.58 %
I Quarter March -93.18 % 20.32 % 7.38 % 3.9 %
FY   - 143.63 % -5.04 % -47.72 %

Financial Statements
Gilead Sciences Inc 's first quarter 2022 Operating Income $ 197.00 millions GILD's Income Statement
Gilead Sciences Inc 's first quarter 2021 Operating Income $ 2,890.00 millions Quarterly GILD's Income Statement
New: More GILD's historic Operating Income Growth >>


GILD Operating Income (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - -75.53 % 32.48 % -
III Quarter September - 71.06 % - -
II Quarter June - -22.28 % - 8.63 %
I Quarter March -79.04 % 9.02 % 119.76 % 95.54 %
FY (Year on Year)   - 143.63 % -5.04 % -47.72 %




Operating Income first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #23
Healthcare Sector #148
Overall #1927

Operating Income Y/Y Growth Statistics
High Average Low
2136.92 % 41.57 % -48.57 %
(Dec. 31, 2007)   (Sep 30 2019)
Operating Income first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #23
Healthcare Sector #148
Overall #1927
Operating Income Y/Y Growth Statistics
High Average Low
2136.92 % 41.57 % -48.57 %
(Dec. 31, 2007)   (Sep 30 2019)

Operating Income by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Gilead Sciences Inc 's Q/Q Operating Income Growth


Operating Income Q/Q Growth Statistics
High Average Low
154.18 % 7.84 % -84.25 %
(March 31, 2014)  


GILD's I. Quarter Q/Q Operating Income Comment
In the I. Quarter 2022 Gilead Sciences Inc realized fall in Operating Income sequentially by -79.04% to $ 197.00 millions, from $ 940.00 millions declared in the previous quarter.

Although cyclical influence commonly elevate I. Quarter 2022 results, this simply was not substantial to salvage Biotechnology & Pharmaceuticals's company I. Quarter 2022 achievement, Giorgi Tavares, Biotechnology & Pharmaceuticals industry advisor pointed out and continued that average quarter on quarter Operating Income growth is at 7.84% for GILD.

Within Biotechnology & Pharmaceuticals industry 17 other companies have achieved higher Operating Income quarter on quarter growth. While Gilead Sciences Inc 's Operating Income growth quarter on quarter, overall rank is 2090.


Operating Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #18
Healthcare Sector #154
Overall #2090
Operating Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #18
Healthcare Sector #154
Overall #2090
Operating Income Q/Q Growth Statistics
High Average Low
154.18 % 7.84 % -84.25 %
(March 31, 2014)  


GILD's I. Quarter Q/Q Operating Income Comment
In the I. Quarter 2022 Gilead Sciences Inc realized fall in Operating Income sequentially by -79.04% to $ 197.00 millions, from $ 940.00 millions released in the previous quarter.

Those cyclical circumstance which commonly fuel I. Quarter 2022 results, could not rescue the I. Quarter for the Gilead Sciences Inc , Giorgi Tavares, Biotechnology & Pharmaceuticals industry advisor wrote, he voiced little caution towards GILD's direction, he detected new difficulties down the road for Gilead Sciences Inc and continued that average sequential Operating Income growth is at 7.84% for Gilead Sciences Inc .

Within Biotechnology & Pharmaceuticals industry 17 other companies have achieved higher Operating Income quarter on quarter growth. While Gilead Sciences Inc 's Operating Income growth quarter on quarter, overall rank is 2090.


Gilead Sciences Inc 's 12 Months Operating Income Growth Year on Year


Operating Income TTM Growth

12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
12 Months Ending
(Jun 30 2021)
12 Months Ending
(Mar 31 2021)
Cumulative Operating Income 12 Months Ending $ 7,225.00 $ 9,918.00 $ 11,629.00 $ 9,788.00 $ 4,559.00
Y / Y Operating Income Growth (TTM) 58.48 % 143.63 % 362.75 % - 2.4 %
Year on Year Operating Income Growth Overall Ranking # 527 # 375 # 88 # 0 # 1191
Seqeuential Operating Income Change (TTM) -27.15 % -14.71 % 18.81 % 114.7 % 11.99 %
Seq. Operating Income Growth (TTM) Overall Ranking # 1927 # 1472 # 340 # 98 # 679




Cumulative Operating Income growth Comment
With the quarterly Operating Income reported in the Mar 31 2022 period, Gilead Sciences Inc 's cumulative twelve months Operating Income were $ 7,225 millions, company would post below average annual Operating Income growth of 11.99% year on year, if the fiscal year would end at Mar 31 2022.
A slow-down in the Gilead Sciences Inc 's Operating Income growth from the 940% growth in Dec 31 2021.

In the Healthcare sector 38 other companies have achieved higher trailing twelve month Operating Income growth. While Operating Income growth total ranking has deteriorated compare to previous quarter from 375 to 527.

Operating Income TTM Q/Q Growth Statistics
High Average Low
2136.92 %
41.57 %
-48.57 %
 

Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 23
Healthcare Sector # 39
Overall # 527

Operating Income TTM Y/Y Growth Statistics
High Average Low
2464.91 %
69.66 %
-91.63 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 23
Sector # 148
S&P 500 # 1927
Cumulative Operating Income growth Comment
With the quarterly Operating Income reported in the Mar 31 2022 period, Gilead Sciences Inc 's cumulative twelve months Operating Income were $ 7,225 millions, company would post below average annual Operating Income growth of -91.63% year on year, if the fiscal year would end at Mar 31 2022.
A slow-down in the Gilead Sciences Inc 's Operating Income growth from the 940% growth in Dec 31 2021.

In the Healthcare sector 38 other companies have achieved higher trailing twelve month Operating Income growth. While Operating Income growth total ranking has deteriorated compare to previous quarter from 375 to 527.

Operating Income TTM Q/Q Growth Statistics
High Average Low
2136.92 %
41.57 %
-48.57 %
 


Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 23
Healthcare Sector # 39
Overall # 527

Operating Income TTM Y/Y Growth Statistics
High Average Low
2464.91 %
69.66 %
-91.63 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 23
Sector # 148
S&P 500 # 1927




Other Operating Income Growth
Biotechnology & Pharmaceuticals Industry Operating Income Growth Trends and Statistics
Healthcare Sector Operating Income Growth Statistics
Operating Income Growth Trends for overall market
GILD's Operating Income Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Operating Income Growth
Lowest Ranking Operating Income Growth
Operating Income Growth for GILD's Competitors
Operating Income Growth for Gilead Sciences Inc 's Suppliers
Operating Income Growth for GILD's Customers

You may also want to know
GILD's Annual Growth Rates GILD's Profitability Ratios GILD's Asset Turnover Ratio GILD's Dividend Growth
GILD's Roe GILD's Valuation Ratios GILD's Financial Strength Ratios GILD's Dividend Payout Ratio
GILD's Roa GILD's Inventory Turnover Ratio GILD's Growth Rates GILD's Dividend Comparisons



Companies with similar Operating Income fall for the quarter ending Mar 31 2022 within Healthcare SectorY/Y Change %Operating Income for the quarter ending Mar 31 2022
Lemaitre Vascular Inc-0.21%$ -0.214 millions
Intuitive Surgical Inc -2.09%$ -2.087 millions
Innoviva Inc -2.21%$ -2.207 millions
Stryker Corp-2.61%$ -2.614 millions
National Research Corporation-2.69%$ -2.687 millions
Diffusion Pharmaceuticals Inc -2.77%$ -2.773 millions
Msa Safety Inc-3.11%$ -3.111 millions
Nuvasive Inc-3.28%$ -3.282 millions
Royalty Pharma Plc-4.18%$ -4.178 millions
Phibro Animal Health Corp-4.66%$ -4.659 millions
Co diagnostics Inc.-4.94%$ -4.942 millions
National Healthcare Corp-6.60%$ -6.602 millions
Natus Medical Inc-7.50%$ -7.500 millions
Dexcom Inc -10.02%$ -10.022 millions
Biomx Inc -10.20%$ -10.196 millions
Pacira Biosciences inc -10.52%$ -10.516 millions
Align Technology inc -12.14%$ -12.138 millions
Lifevantage Corp-12.60%$ -12.596 millions
Tivity Health Inc -12.86%$ -12.858 millions
Rackspace Technology Inc -13.64%$ -13.636 millions
Diversified Healthcare Trust-15.19%$ -15.194 millions
Petmed Express Inc-15.86%$ -15.858 millions
Community Health Systems Inc -17.18%$ -17.178 millions
Fonar Corporation-18.88%$ -18.878 millions
Universal Health Services Inc -21.24%$ -21.244 millions
Molecular Templates Inc -21.64%$ -21.642 millions
Quest Diagnostics Inc-22.27%$ -22.273 millions
Davita Inc -23.56%$ -23.564 millions
Fulgent Genetics Inc -24.35%$ -24.348 millions
Zimmer Biomet Holdings Inc -25.30%$ -25.301 millions


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

WWSG's Profile

Stock Price

WWSG's Financials

Business Description

Fundamentals

Charts & Quotes

WWSG's News

Suppliers

WWSG's Competitors

Customers & Markets

Economic Indicators

WWSG's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071